Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score N/A
- Piotroski Score 7.00
- Grade Outperform
- Symbol (GILD)
- Company Gilead Sciences, Inc.
- Price $97.91
- Changes Percentage (6.78%)
- Change $6.22
- Day Low $93.51
- Day High $98.32
- Year High $98.32
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
- Last Earnings 08/08/2024
- Ex-Dividend for 5/16 Dividend 09/13/2024
- Dividend Payable 09/27/2024
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $83.50
- High Stock Price Target $105.00
- Low Stock Price Target $54.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.36
- Trailing P/E Ratio 179.72
- Forward P/E Ratio 179.72
- P/E Growth 179.72
- Net Income $5.67 B
Income Statement
Quarterly
Annual
Latest News of GILD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Former 'Real Housewives' star Dorinda Medley shows off lavish Gilded Age estate
Dorinda Medley, former "Real Housewives of New York City" star, showcases her renovated Berkshires estate on Open House TV....
By MarketWatch | 17 hours ago -
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
Gilead Sciences reported strong third quarter results with growth across HIV, oncology, and liver disease segments....
By Yahoo! Finance | 1 day ago -
Is Gilead Sciences, Inc. (GILD) the Best Pharma Stock to Buy Right Now?
Discover the top 10 Pharma Stocks to invest in now, focusing on Gilead Sciences, Inc. The pharmaceutical industry is rapidly evolving with breakthroughs in medical technology and treatments, attractin...
By Yahoo! Finance | 3 days ago
